Neuropathic Pain Market Trends and Forecast

1. Neuropathic Pain Market to Grow at a Substantial Growth Rate During the Forecast Period Estimates DelveInsight (2022-2032) - The Neuropathic Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuropathic Pain pipeline products will significantly revolutionize the Neuropathic Pain market dynamics. DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Neuropathic Pain, historical and forecasted epidemiology as well as the Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Neuropathic Pain Overview According to the International Association for the Study of Pain (IASP), neuropathic pain is defined as “pain initiated or caused by a primary lesion or dysfunction in the nervous system. Chronic neuropathic

2. pain is common and may be related to an underlying health condition such as cancer or diabetic neuropathy, or it could be related to treatments such as chemotherapy. Common causes of neuropathic pain include nerve pressure or nerve damage after surgery or trauma, viral infections, cancer, vascular malformations, alcoholism, neurological conditions such as multiple sclerosis, and metabolic conditions such as diabetes. Neuropathic Pain Symptoms The Neuropathic Pain symptoms include - ● ● ● ● Spontaneous pain Burning, stabbing, and tingling feeling Shooting Stabbing pain Some of the key facts of the Neuropathic Pain Market Report: ● The Neuropathic Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032) According to Bouhassira D, the prevalence of neuropathic pain in the general population may be as high as 7 to 8%, accounting for 20 to 25% of individuals with chronic pain In a study by Pottathil S et.al, the incidence of chronic neuropathic pain is 10–14% in the United Kingdom, 9.8–12.4% in the United States, and 7–10% worldwide Key Neuropathic Pain Companies: Bayer, WEX Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, and others Key Neuropathic Pain Therapies: Halneuron, LX9211, BAY2395840, and others Halneuron which is expected to launch during the forecast period (2022–2032), is believed to be the most successful therapy amongst all the other expected drug candidates and shall account for the highest market revenue in the coming years The Neuropathic Pain epidemiology based on gender analyzed that Neuropathic Pain affects females more as compared to males According to Cavalli E et.al neuropathic pain was more prevalent among women (60.5% of patients) and reached a peak at 50–64 years of age ● ● ● ● ● ● ● ● Get a Free sample for the Neuropathic Pain Market Report Key benefits of the Neuropathic Pain Market report: 1. Neuropathic Pain market report covers a descriptive overview and comprehensive insight of the Neuropathic Pain Epidemiology and Neuropathic Pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) The Neuropathic Pain market report provides insights on the current and emerging therapies. Neuropathic Pain market report provides a global historical and forecasted market covering drug outreach in 7MM. The Neuropathic Pain market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Neuropathic Pain market. 2. 3. 4.

3. Discover more about therapies set to grab major Neuropathic Pain market share @ Neuropathic Pain market forecast Neuropathic Pain Epidemiology Segmentation: The Neuropathic Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: ● ● ● ● Total Prevalence of Neuropathic Pain Prevalent Cases of Neuropathic Pain by severity Gender-specific Prevalence of Neuropathic Pain Diagnosed Cases of Episodic and Chronic Neuropathic Pain Neuropathic Pain Market The dynamics of the Neuropathic Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. “The approval of novel therapies for the treatment of neuropathic pain has led to a major uptick in the DNP drugs market. For instance, in January 2022, US FDA approved the Senza Omnia spinal cord stimulation (SCS) system for chronic neuropathic pain treatment. Another drug, Tarlige (Mirogabalin besylate), was approved by PMDA Japan for Neuropathic Pain in 2022.” Download the report to understand which factors are driving Neuropathic Pain epidemiology trends @ Neuropathic Pain Epidemiological Insights Neuropathic Pain Therapies ● ● ● Halneuron LX9211 BAY2395840 Neuropathic Pain Key Companies ● ● ● Bayer WEX Pharmaceuticals Inc Lexicon Pharmaceuticals Inc Scope of the Neuropathic Pain Market Report ● ● Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Neuropathic Pain Companies: Bayer, WEX Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, and others Key Neuropathic Pain Therapies: Halneuron, LX9211, BAY2395840, and others Therapeutic Assessment: Neuropathic Pain current marketed and Neuropathic Pain emerging therapies Neuropathic Pain Market Dynamics: Neuropathic Pain market drivers and barriers ● ● ● ●

4. ● Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Neuropathic Pain Reimbursement ● Market Access and To know more about Neuropathic Pain treatment, visit @ Neuropathic Pain Medications Related Reports: Neuropathic Pain Pipeline "Neuropathic Pain Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neuropathic Pain market. A detailed picture of the Neuropathic Pain pipeline landscape is provided, which includes the disease overview and Neuropathic Pain treatment guidelines. Neuropathic Pain Epidemiology DelveInsight's 'Neuropathic Pain Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neuropathic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the

5. therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Ventricular Assist Devices (VAD) Market Ventricular Assist Devices (VAD) Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services Also, take a glance at the Blogs by DelveInsight: ● ● ● ● How Metaverse is Set to Transform the Healthcare Dynamics? Role of Mobile Technology in Hemophilia Management How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry? How Cloud Computing is Transforming the Healthcare Industry Dynamics?